Apollo Tyres Limited. · NSE:APOLLOTYRE
Apollo Tyres — Q1 FY27 Earnings Presentation
12 slides from Apollo Tyres's earnings presentation, Aug 7, 2026
Slide 1: Investor Presentation Q1 FY27 exchange intimation letter
ATL/SEC/21 August 7, 2026 The Secretary, The Secretary, BSE Ltd. National Stock Exchange of India Ltd, Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra-Kurla Complex, Mumbai – 400001. Bandra (E), Mumbai - 400 051 Sub: Investor Presentation-Q1 FY27 Dear Sirs, Pursuant to Regulation 30(
Slide 2: Earnings Presentation | Q1 FY27
Earnings Presentation | Q1 FY27
Slide 3: Disclaimer
Disclaimer These materials have been prepared by Apollo Tyres Limited together with its subsidiaries (the “Company”), are for informational purposes only and do not constitute a prospectus or an offer document, or form part of an offer, solicitation or invitation of any offer to purchase or subscrib
Slide 4: Consolidated Financial Snapshot
Consolidated Financial Snapshot Q1 FY27 Financial Performance FY26 Financial Performance Revenue EBITDA EBITDA Margins Revenue EBITDA EBITDA Margins INR 73,978 Mn INR 8,680 Mn 11.7% INR 284,706 Mn INR 41,432 Mn 14.6% Y-o-Y Y-o-Y Y-o-Y Y-o-Y Y-o-Y Y-o-Y +12.8% +0.0% -149 Bps +9.0% +16.0% +88 Bps ROCE
Slide 5: Performance Summary – Q1 FY27
Performance Summary – Q1 FY27 Revenue MixConsolidated Revenue Mix Consolidated– –YTD Q1 FY22 FY27 Consolidated Consolidated By Region Others, Revenue EBITDA (Margin) 5% ~INR 74.0 Bn ~INR 8.7 Bn (11.7%) Europe1, Capacity Utilization 26% India Europe India, 91% 94% 69% Note: 1. Europe Includes operati
Slide 6: Operating Highlights – India
Operating Highlights – India Q1 FY27 Revenue (INR Mn) 54,619 • In Q1FY27, we delivered our strongest year-on-year quarterly growth (15.6%) in the last 14 quarters, following a strong double digit growth in the last quarter 47,254 • Double-digit growth across Replacement, OE & Export markets and key
Slide 7: Operating Highlights – Europe
Operating Highlights – Europe1 Q1 FY27 Revenue (€ Mn) • Volumes witnessed low single digit growth on a YoY basis +0.5% 147 • The PCR Replacement segment continues to deliver 146 healthy growth and the positive momentum is expected to sustain through the coming quarters • EBITDA margins reduced by 18
Slide 8: Consolidated Cash Flow & Balance Sheet Highlights
Consolidated Cash Flow & Balance Sheet Highlights Capex (INR Bn) 14 Key Highlights 8 • Leverage remains stable, with the Net Debt/ EBITDA ratio unchanged FY25 FY26 Free Cash flow (INR Bn) 20 13 FY25 FY26 2.0 Net Debt (INR Bn) 17 16 0.4 0.4 10 0.0 FY26 Jun-26 Net Debt (INR Bn) Net Debt to EBITDA (x)
Slide 9: Financial Statements
Financial Statements
Slide 10: Profit & Loss (Quarterly) – Consolidated
Profit & Loss (Quarterly) – Consolidated Particulars (INR Mn) Q1 FY27 Q1 FY26 Q4 FY26 % Change - YoY % Change - QoQ Revenues 73,978 65,608 73,357 12.8% 0.8% Raw Material 42,221 36,684 38,896 Staff Cost 9,628 8,696 8,848 Other Costs 13,449 11,550 14,925 EBITDA 8,680 8,677 10,688 0.0% -18.8% EBITDA Ma
Slide 11: Profit & Loss (Quarterly) – Standalone
Profit & Loss (Quarterly) – Standalone Particulars (INR Mn) Q1 FY27 Q1 FY26 Q4 FY26 % Change - YoY % Change - QoQ Revenues 54,619 47,254 52,370 15.6% 4.3% Raw Material 35,973 29,925 31,625 Staff Cost 3,426 3,241 3,319 Other Costs 8,672 7,640 9,785 EBITDA 6,549 6,447 7,641 1.6% -14.3% EBITDA Margin (
Slide 12: Thank you
For further details please feel free to get in touch Ritu Kumar with the Investor Relations team. Group Head – Strategic Planning and Legal [email protected] Thank you